Vapotherm Hosts Sold–Out Symposium on High Flow Therapy for the Neonate

Stevensville, Maryland, December 6, 2012:

Vapotherm hosted 300 neonatologists at a lunchtime symposium at the Hot Topics in Neonatology Meeting in Washington DC on Tuesday, December 4. The symposium titled, High Flow Therapy in the NICU: Practical Applications and Clinical Pathway, followed two podium presentations on multi-center studies comparing high flow therapy to traditional pressure therapy.

The symposium allowed experienced users to share their thoughts on best practice implementation and expected outcomes with Vapotherm high flow therapy in the neonatal ICU. Neonatologists implementing high flow therapy are looking for practical advice on patient selection, flow rates, and other aspects of appropriate clinical use.

The symposium was chaired by Dr. Michael McQueen from Banner Health System, Phoenix, AZ, who shared his experience in improving clinical outcomes and reducing overall cost of care though the use of Vapotherm High Flow Therapy. He was joined by Dr. Kevin Ives speaking on the approach used to treat patients for over eight years in the NICU at John Radcliffe Hospital in Oxford, UK. Dr. Paolo Tagliabue spoke about the increasing acceptance of high flow therapy in Italy. Finally, Dr. Amir Kugleman presented recent research showing that high flow therapy compares favorably with Nasal Intermittent Positive Pressure Ventilation (NIPPV).

High Flow Therapy is rapidly becoming the first choice for respiratory support of neonates. Vapotherm therapy provides ventilatory support for high acuity patients, yet is non-intrusive and patient friendly. Patients, caregivers and families appreciate that it provides highly effective respiratory support without a tube, mask or tight fitting nasal prongs. Babies can comfortably sleep, feed and be cuddled.

Vapotherm, Inc. is a privately held manufacturer of respiratory care devices for hospitals and home care use based in Stevensville, Maryland. The Company is dedicated to the development of innovative, noninvasive technologies for respiratory patients, especially for the treatment of chronic lung and acute breathing disorders.

2017-07-24T23:52:26-04:00Dec 6|Vapotherm Company News|
Go to Top